Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE)
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
The company claims to be a market leader in core orthopaedic and gynaecology segments like bone and joint disorders, pain management and, pregnancy and women’s nutrition
Takeda to exclusively commercialize JR-141 outside the U.S. (except Japan and certain other Asia-Pacific countries) upon regulatory approval
The acquisition complements and strengthens Merck’s cardiovascular pipeline
Remote screening of diabetic retinopathy can help in early detection, even before there are any noticeable vision changes
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
The hospital through its network performs more than 10,000 joint replacement surgeries annually
Extension of hypericin orphan designation beyond cutaneous T-cell lymphoma
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
Subscribe To Our Newsletter & Stay Updated
